ArticleInternational journal of clinical and experimental pathology2019
miR-135a acts as a tumor suppressor by targeting ASPH in endometrial cancer.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- Circ_0005699 Expedites ox-LDL-Triggered Endothelial Cell Injury via Targeting miR-384/ASPH Axis.Cardiovascular toxicology · 2024Article
- The interplay of sex steroid hormones and microRNAs in endometrial cancer: current understanding and future directions.Frontiers in endocrinology · 2023Review
- miR-29a-3p inhibits endometrial cancer cell proliferation, migration and invasion by targeting VEGFA/CD C42/PAK1.BMC cancer · 2021Article
- Review
- CircTM7SF3 contributes to oxidized low-density lipoprotein-induced apoptosis, inflammation and oxidative stress through targeting miR-206/ASPH axis in atherosclerosis cell model in vitro.BMC cardiovascular disorders · 2021Article
- Identification of a MicroRNA Signature Associated With Lymph Node Metastasis in Endometrial Endometrioid Cancer.Frontiers in genetics · 2021Article
- Diverse molecular functions of aspartate β‑hydroxylase in cancer (Review).Oncology reports · 2020Review
- Aspartate β-hydroxylase as a target for cancer therapy.Journal of experimental & clinical cancer research : CR · 2020Review
- miR-135a inhibits malignant proliferation and diffusion of non-small cell lung cancer cells by down-regulating ROCK1 protein.Bioscience reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) ranks as the fourth most commonly diagnosed cancer type in women worldwide. MicroRNAs (miRNAs) are important regulators with crucial roles in regulating diverse biologic processes, including tumor initiation and progression. Previous studies have demonstrated that miR-135a was correlated with tumorigenesis in various cancers. However, its expression and biologic role in EC remained to be determined. This study aimed to clarify whether miR-135a acts as a tumor suppressor in EC by regulating the expression of aspartate-β-hydroxylase (ASPH). Expression of miR-135a was measured by qRT-PCR and the results demonstrated that miR-135a was downregulated in EC cell lines compared to a normal cell line. Cell counting kit-8 (CCK-8) and wound-healing assays demonstrated that overexpression of miR-135a significantly inhibited cell proliferation and migration. Online prediction algorithm and dual luciferase activity reporter assay revealed that ASPH acts as a direct target of miR-135a. ASPH expression was downregulated in EC cell lines when miR-135a was overexpressed. Collectively, our results indicate that miR-135a targets ASPH to inhibit EC cell proliferation and migration, suggesting a tumor suppressive role of miR-135a in EC.
Indexed as
Identifiers
31934181PMC6949859W3018656878What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.